Dermatology

  • Oral hyperpigmentation with weakness and salt-craving
    Joseph Zhou, MD and S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 180-181; DOI: https://doi.org/10.3949/ccjm.89a.21036

    The patient’s primary care physician had attributed the hyperpigmentation on the lower lip and inner cheek to pen ink.

  • Potential systemic benefits of shocking or blocking nerves
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 119-120; DOI: https://doi.org/10.3949/ccjm.89b.03022

    What has really caught my attention is the expanding research on controlled regional neuromodulation and its impact on systemic physiology and inflammation.

  • Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Yeonsoo Sara Lee, BS, Christopher Wie, MD, Scott Pew, MD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 147-153; DOI: https://doi.org/10.3949/ccjm.89a.21032

    Hormone therapy is the mainstay of treatment, but there is a clear need for safe and effective nonhormonal options. The authors review data on the use of stellate ganglion block in perimenopausal and postmenopausal patients.

  • Vitamin D supplementation: Pearls for practicing clinicians
    Susan E. Williams, MS, RD, MD, CCD, FACE, FAND
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 154-160; DOI: https://doi.org/10.3949/ccjm.89a.21021

    A review of how to assess and counsel patients on the use of vitamin D, with patient scenarios clinicians are likely to encounter, and an overview of current recommendations for vitamin D supplementation.

  • Common skin signs of COVID-19 in adults: An update
    Samantha Polly, MD and Anthony P. Fernandez, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 161-167; DOI: https://doi.org/10.3949/ccjm.89a.21126

    Cutaneous findings can be clues to the diagnosis and infection severity in viral illnesses, including COVID-19.

  • Hypertrichosis and topical corticosteroid use
    Yuya Ando, MD, Sachiko Ono, MPH, PhD, Yosuke Ono, MD, PhD and Yoshinori Miura, MD, PhD
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 71-72; DOI: https://doi.org/10.3949/ccjm.89a.21048

    The xerotic dermatitis had resolved 2 years earlier, but the patient had continued to apply the medication.

  • Soft tissue sarcoma: Recognizing a rare disease
    Amir Hossain Gahanbani Ardakani, BSc, MBBS, Alex Woollard, BM, BSc, PhD, FRCS (Plast), Howard Ware, MBBS, FRCS (Tr&Orth) and Panagiotis Gikas, MBBS Hons, MD (Res), PhD, FRCS (Tr&Orth)
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 73-80; DOI: https://doi.org/10.3949/ccjm.89a.21078

    Awareness of the signs and symptoms ensures prompt referral to a sarcoma center for appropriate assessment and treatment to optimize outcomes.

  • A large, painless bulla on the right foot
    Jorge Camilo Mora, MD, MPH and Amalia Galindez, MD, FACP
    Cleveland Clinic Journal of Medicine January 2022, 89 (1) 10-12; DOI: https://doi.org/10.3949/ccjm.89a.21051

    A patient with a history of type 2 diabetes and diabetic neuropathy had a hemoglobin A1c of 10.3% at presentation.

  • A perspective on discussing COVID-19 vaccines: Efficacy and adverse effects
    Brian F. Mandell, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 644-645; DOI: https://doi.org/10.3949/ccjm.88b.12021

    Physicians should be vigilant and open-minded regarding possible adverse reactions to the vaccines, and should take time to discuss the demonstrated efficacy of vaccines with patients.

  • COVID-19 vaccine-induced cellulitis and myositis
    Sathishkumar Ramalingam, MD, Harkesh Arora, MD, Susan Lewis, MD, Kulothungan Gunasekaran, MD, Maheswari Muruganandam, MD, Sivakumar Nagaraju, MD and Priyesh Padmanabhan, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 648-650; DOI: https://doi.org/10.3949/ccjm.88a.21038

    The day after receiving the second dose of the mRNA vaccine, redness and pain developed at the injection site, eventually involving the whole left arm and shoulder.

Pages